Cancer is a complex disease that has affected millions of people worldwide. Although significant strides have been made in cancer research, there is still much to be done. Infinity Pharmaceuticals is a biopharmaceutical company that has been at the forefront of cancer research and development of innovative therapies. This feature will discuss the company’s history, milestones, and the leadership of its CEO, Adelene Perkins.
How It All Began….
Infinity Pharmaceuticals was founded in 2001, with a vision to develop innovative therapies that could change the course of cancer treatment. The company’s focus is on discovering, developing, and delivering small molecule drugs that target cancer cells’ specific pathways. Infinity Pharmaceuticals’ drug discovery platform, known as the Integrated Drug Discovery Engine, uses a combination of genomics, computational chemistry, and high-throughput screening to identify potential drug candidates.
In 2010, Infinity Pharmaceuticals received approval from the US Food and Drug Administration (FDA) for its first drug, IPI-145, a selective inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The drug was developed for the treatment of hematologic malignancies, including chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma (iNHL). The approval was a significant milestone for the company, and it marked its transition from a research-focused organization to a fully integrated biopharmaceutical company.
Under the Stewardship of an Pharma Expert
Adelene Perkins is the CEO of Infinity Pharmaceuticals, a role she has held since 2009. Perkins has over 25 years of experience in the biopharmaceutical industry, with a focus on strategic planning, business development, and commercialization of innovative therapies. Before joining Infinity Pharmaceuticals, Perkins held various executive positions at Vertex Pharmaceuticals, including Senior Vice President of Corporate Development and Vice President of Business Development.
Under Perkins’ leadership, Infinity Pharmaceuticals has made significant progress in developing innovative cancer therapies. In addition to IPI-145, the company has several other drug candidates in its pipeline, targeting various cancer pathways, including fibroblast growth factor receptor (FGFR) and heat shock protein 90 (Hsp90). Perkins has been instrumental in forging strategic partnerships and collaborations that have enabled the company to expand its research capabilities and accelerate its drug development programs.
Collaborations and Partnerships
Infinity Pharmaceuticals has established strategic partnerships and collaborations with other biopharmaceutical companies, academic institutions, and research organizations to advance its drug development programs. In 2019, the company entered into a collaboration with Arcus Biosciences to develop a novel cancer therapy that targets the adenosine pathway. The collaboration leverages Infinity Pharmaceuticals’ expertise in drug discovery and Arcus Biosciences’ experience in developing immunotherapies.
In addition, the company has a collaboration with the National Cancer Institute (NCI) to evaluate IPI-549, an inhibitor of phosphoinositide-3-kinase (PI3K)-gamma, in combination with a checkpoint inhibitor in patients with advanced solid tumors. The collaboration aims to evaluate the safety and efficacy of the combination therapy and identify patients who are likely to benefit from the treatment.
Infinity Pharmaceuticals is a biopharmaceutical company that has made significant progress in developing innovative cancer therapies. Its drug discovery platform and strategic collaborations have enabled the company to accelerate its drug development programs and bring promising growth in the future.